Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/ijms23063068
Keywords
vasopressin; vasopressin analogues; vasoconstrictors; vasopressin receptors; desmopressin
Funding
- National Science Center Poland (NCN) [UMO 2019/35/D/NZ7/00174]
Ask authors/readers for more resources
This article discusses the synthesis and functions of human neurohormone vasopressin (AVP), as well as the efforts and applications in finding AVP analogues. Natural and synthetic AVP analogues play important therapeutic roles in medicine, such as lypressin and terlipressin. Recent research also explores the potential applications of AVP analogues in the treatment of SARS-CoV-2.
Human neurohormone vasopressin (AVP) is synthesized in overlapping regions in the hypothalamus. It is mainly known for its vasoconstricting abilities, and it is responsible for the regulation of plasma osmolality by maintaining fluid homeostasis. Over years, many attempts have been made to modify this hormone and find AVP analogues with different pharmacological profiles that could overcome its limitations. Non-peptide AVP analogues with low molecular weight presented good affinity to AVP receptors. Natural peptide counterparts, found in animals, are successfully applied as therapeutics; for instance, lypressin used in treatment of diabetes insipidus. Synthetic peptide analogues compensate for the shortcomings of AVP. Desmopressin is more resistant to proteolysis and presents mainly antidiuretic effects, while terlipressin is a long-acting AVP analogue and a drug recommended in the treatment of varicose bleeding in patients with liver cirrhosis. Recently published results on diverse applications of AVP analogues in medicinal practice, including potential lypressin, terlipressin and ornipressin in the treatment of SARS-CoV-2, are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available